Skip NavigationSkip to Content
Return Return to Search Results

Bone marrow deficient in IFN-gamma signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect

  1. Author:
    Capitini, C. M.
    Herby, S.
    Milliron, M.
    Anver, M. R.
    Mackall, C. L.
    Fry, T. J.

  2. Author Address

    Capitini, Christian M.; Herby, Sarah, Milliron, Matthew, Mackall, Crystal L.; Fry, Terry J.] NCI, Immunol Sect, Pediat Oncol Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA. [Anver, Miriam R.] NCI, Pathol Histotechnol Lab, Sci Applicat Int Corp SAIC Frederick, NIH, Frederick, MD 21701 USA. [Fry, Terry J.] Childrens Natl Med Ctr, Ctr Canc & Blood Disorders, Washington, DC 20010 USA.
    1. Year: 2009
  2. Journal: Blood
    1. 113
    2. 20
    3. Pages: 5002-5009
  4. Type of Article: Article
  1. Abstract:

    Vaccine-based expansion of T cells is one approach to enhance the graft-versus-tumor effect of allogeneic bone marrow transplantation (BMT), but the complex immunobiology of the allogeneic environment on responses to tumor vaccines has not been well characterized. We hypothesized that subclinical graft-versus-host disease (GVHD) impairs immunity, but modulation of gamma interferon (IFN-gamma) signaling could reverse this effect. Dendritic cell vaccines and donor lymphocyte infusions (DLIs) were incorporated into a minor histocompatibility antigen-mismatched, T cell-depleted, allogeneic BMT mouse model. Animals were then challenged with H-Y expressing tumors. CD4(+) and CD8(+) responses to H-Y were diminished in vaccinated allogeneic versus syngeneic BMT recipients with DLI doses below the threshold for clinical GVHD, especially in thymectomized hosts. IFN-gamma receptor 1-deficient (IFN-gamma R1(-/-)) T cells cannot cause GVHD but also have diminished vaccine responses. Remarkably, IFN-gamma R1(-/-) bone marrow abrogates GVHD, allowing higher DLI doses to be tolerated, but improves vaccine responses and tumor protection. We conclude that tumor vaccines administered after allogeneic BMT can augment graft-versus-tumor if GVHD is avoided and that prevention of IFN-gamma signaling on donor bone marrow is an effective approach to preventing GVHD while preserving immunocompetence. (Blood. 2009, 113: 5002-5009)

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1182/blood-2008-11-187385
  3. PMID: 19258593

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel